ClinicalTrials.gg
Status unknownNCT04352725TIPEX-VOLTEXUpdated Apr 20, 2020

Effect of PEEP Titration on the EELV Measured by the Nitrogen Dilution Technique in ARDS

An interventional study of End-expiratory lung volume measurement and incremental PEEP titration in Acute Respiratory Distress Syndrome, sponsored by Centre Hospitalier Intercommunal Aix-Pertuis. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-20.

Sponsored by Centre Hospitalier Intercommunal Aix-Pertuis · Not applicable, Interventional, and Supportive care

How we know

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 217 studies in Respiratory Distress Syndrome with a site in France — 41 open to participants now, 43 under way, 7 of them phase 3. Respiratory Distress Syndrome · France.

Planned enrollment
63rd of 118
40 · median 50
Started
2020
with 60 others
No phase
77 of 217
14 open now
Registered
100th of 217
by date

Among the 217 studies in Respiratory Distress Syndrome with a site in France, this one is the 63rd largest by planned enrollment of the 118 interventional ones that give a count, is one of 61 that started in 2020, is one of 77 with no phase, and was the 100th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

41 of the 217 studies in Respiratory Distress Syndrome with a site in France are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Respiratory Distress Syndrome with a site in France, or all of them as a file.
02

Study summary

Mechanical ventilation of the patient with acute respiratory distress syndrome is one of the first therapies.

Read the detailed description

The application of positive end expiratory pressure is recommended but the question remains "How to set the best positive end-expiratory pressure (PEEP) level for each patient? ". Different titration techniques have been studied on oxygenation and respiratory mechanics parameters without reaching a consensus. Currently we have a module that is connected to the ventilator to collect the patient's lung volume. It will therefore allow us to optimize the settings of the ventilator and to set the best level of positive end-expiratory pressure "best peep" in order to individualize our treatment for each patient.

03

Conditions studied

  • Acute Respiratory Distress Syndrome

Keywords

  • respiratory distress
  • titration
  • end-expiratory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients admitted to intensive care with a diagnosis of moderate to severe ARDS in accordance with the Berlin criteria, i.e. a PAFI \<200 and PEEP >5cm H20 ratio
  • Diagnosis of ARDS made within 72 hours
  • Age over 18 years
  • of the patient and/or trusted person where applicable

Exclusion criteria

Exclusion Criteria:

  • Start of mechanical ventilation more than 72 hours prior to inclusion.
  • SDRA evolving for more than 72 hours
  • Presence of major hemodynamic instability with mean blood pressure \<60mmhg, and/or heart rate \<45 bpm or >150bpm with an increase in vasopressor amine dosage of more than 20% over the last 6 hours.
  • Intracranial hypertension with CPP\<60mmhg
  • Massive hemoptysis requiring immediate surgical or interventional radiology procedure
  • Tracheal surgery (except intensive care tracheotomy) or sternotomy within the previous 15 days
  • Trauma or surgery of the face in the previous 15 days.
  • Deep vein thrombosis treated for less than 2 days
  • Pacemaker implantation in the last 2 days
  • Unstable fracture (spine, femur or pelvis)
  • Respiratory reasons
  • use of extracorporeal oxygenation
  • nitric oxide
  • pleural drainage system with bronchopleural gap
  • pulmonary transplantation
  • Poor respiratory tolerance per procedure with desaturation Spo2\<85%.
  • Poor hemodynamic tolerability per procedure combining hypotension with MAP\<65mmhg and a 20% increase in norepinephrine dosage.
  • Lack of patient consent to proceed
  • minor patient
  • lack of consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    experimental procedure

    * end-expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat\<28cmH2o * incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o

    Procedure: End-expiratory lung volume measurement and incremental PEEP titration

Interventions

  • ProcedureEnd-expiratory lung volume measurement and incremental PEEP titration

    * End expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat\<28cmH2o * incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o

06

What researchers measure

Primary outcomes

  1. Observe end-expiratory lung volume change during an increasing PEEP titration procedure in patients with moderate to severe ARDS

    Time frame: 1 day

Secondary outcomes

  1. Define a threshold of end-expiratory lung volume variation to help determine optimal PEEP

    Time frame: 1 day

  2. Analyzing the effect of PEEP titration on static compliance and dynamic strain

    Time frame: 1 day

  3. Effect of PEEP titration on hematosis via the calculation of the Pao2/Fio2 ratio for each PEEP step thanks to the measurement of Pao2 on arterial gasometry

    Time frame: 1 day

  4. Study the correlation between % change in end-expiratory lung volume and improvement in hematosis (Pao2/Fio2)

    Time frame: 1 day

  5. Compare end-expiratory lung volume variations according to the type of ARDS (severity, focal or diffuse, pulmonary or extra-pulmonary etiology)

    Time frame: 1 day

  6. Evaluate the hemodynamic tolerance of this procedure with the mean arterial pressure obtained by invasive blood pressure, noradrenaline dosage variation per procedure, lactate (obtained by arterial blood gas)

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
  • Centre Hospitalier Intercommunal Aix-Pertuis
    Aix-en-Provence, 13100, France
    Recruiting
    • Agathe BOULANT · Contactaboulant@live.fr · 0442335650
    • Thibault HELBERT, Dr. · Sub investigator
    • Luc RODRIGUEZ, Dr. · Sub investigator
    • Laurent LEFEBVRE, Dr. · Principal investigator
08

References and documents

Publications

  • Casserly B, McCool FD, Saunders J, Selvakumar N, Levy MM. End-Expiratory Volume and Oxygenation: Targeting PEEP in ARDS Patients. Lung. 2016 Feb;194(1):35-41. doi: 10.1007/s00408-015-9823-6. Epub 2015 Dec 8. PubMed 26645226 ↗
  • Maggiore SM, Jonson B, Richard JC, Jaber S, Lemaire F, Brochard L. Alveolar derecruitment at decremental positive end-expiratory pressure levels in acute lung injury: comparison with the lower inflection point, oxygenation, and compliance. Am J Respir Crit Care Med. 2001 Sep 1;164(5):795-801. doi: 10.1164/ajrccm.164.5.2006071. PubMed 11549535 ↗
  • Olegard C, Sondergaard S, Houltz E, Lundin S, Stenqvist O. Estimation of functional residual capacity at the bedside using standard monitoring equipment: a modified nitrogen washout/washin technique requiring a small change of the inspired oxygen fraction. Anesth Analg. 2005 Jul;101(1):206-12, table of contents. doi: 10.1213/01.ANE.0000165823.90368.55. PubMed 15976233 ↗
  • Sahetya SK, Goligher EC, Brower RG. Fifty Years of Research in ARDS. Setting Positive End-Expiratory Pressure in Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2017 Jun 1;195(11):1429-1438. doi: 10.1164/rccm.201610-2035CI. Erratum In: Am J Respir Crit Care Med. 2018 Mar 1;197(5):684-685. doi: 10.1164/rccm.1976Erratum1. PubMed 28146639 ↗
  • Dellamonica J, Lerolle N, Sargentini C, Beduneau G, Di Marco F, Mercat A, Richard JC, Diehl JL, Mancebo J, Rouby JJ, Lu Q, Bernardin G, Brochard L. PEEP-induced changes in lung volume in acute respiratory distress syndrome. Two methods to estimate alveolar recruitment. Intensive Care Med. 2011 Oct;37(10):1595-604. doi: 10.1007/s00134-011-2333-y. Epub 2011 Aug 25. PubMed 21866369 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Nov 2020, 10 months after the start.

Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 10 months is below that.

Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2020
First posted
Apr 20, 2020
StartActual
Jan 20, 2020
Primary completionEst.
Nov 30, 2020
CompletionEst.
Nov 30, 2020
Last update
Apr 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04352725
Lead sponsor
Centre Hospitalier Intercommunal Aix-Pertuis
Responsible party
Laurent LEFEBVRE (Doctor, rescuer, Centre Hospitalier Intercommunal Aix-Pertuis) — Principal investigator
First posted
Apr 20, 2020
Start date
Jan 20, 2020
Primary completion
Nov 30, 2020 (estimated)
Completion
Nov 30, 2020 (estimated)
Last update
Apr 20, 2020

Study contacts

Agathe BOULANT
Contact
aboulant@live.fr
0442335650 ext. +33
Laurent LEFEBVRE, Dr.
principal investigator · Centre Hospitalier Intercommunal Aix-Pertuis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion